HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN...
Toward a Sustainable Development Community: Chery Group Leads the Future of Mobility Through Global ESG Action
WUHU, China, Oct. 22, 2025 /PRNewswire/ -- As the global automotive industry undergoes a century-defining transformation, a new era of openness and collaboration is emerging. Once a niche investment concept, Environmental, Social, and Governance...
Beatbot's Innovative Pool Robots Secure Prestigious 2025 GOOD DESIGN Award and IDEA Finalist
RICHMOND, Texas, Oct. 22, 2025 /PRNewswire/ -- Beatbot, a global leader in cutting-edge robotic pool cleaning technology, continues its award-winning streak with the announcement that its iSkim Ultra and AquaSense 2 Ultra have received the 2025 GOOD...
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today...
Ampace Showcases More Economical and Efficient Energy Solutions at All Energy Australia 2025
MELBOURNE, Australia, Oct. 22, 2025 /PRNewswire/ -- Ampace will take the stage at All Energy Australia 2025 (Booth GG123), unveiling its latest advances in battery technology and next-generation energy storage solutions. As a trusted energy...
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of...
ENCAPS wins top honours at WRIQ's Lithium Battery Innovation Challenge
BRISBANE, Australia, Oct. 22, 2025 /PRNewswire/ -- The Waste Recycling Industry Association Queensland (WRIQ) has announced ENCAPS as the overall winner of the 2025 Lithium Battery Innovation Challenge, recognising its outstanding contribution to...
GAC at the Canton Fair: Exploring a New Collaborative Model of Globalization for Chinese Enterprises -- Products, Ecosystems, and Culture
GAUNGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- On October 15, as a leading force in China's automotive industry going global, GAC participated in the 138th Canton Fair under the theme "Where Craft Meets Technology." Blending Lingnan cultural...
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...